Showing 2041-2050 of 2657 results for "".
- Viatris Launches First National Direct to Consumer Campaign for Dry Eye Nasal Spray Tyrvayahttps://modernod.com/news/viatris-launches-first-national-direct-to-consumer-campaign-for-dry-eye-nasal-spray-tyrvaya/2481860/After nearly 2 years of educational programs to introduce Tyrvaya (varenicline solution) Nasal Spray to eye care professionals, the Viatris Eye Care Division announced it is rolling out a nationwide, multi-channel campaign. The new campaign, entitled “It’s Not Another Drop,&
- Harrow Health Changes Corporate Name to Harrow Inc.https://modernod.com/news/harrow-health-changes-corporate-name-to-harrow-inc/2481858/Harrow announced that effective today, it has changed its corporate name from “Harrow Health Inc.” to “Harrow Inc.” to align with the company’s current 5-year strategic plan, which includes an exclusive focus on eye care pharmaceuticals. “Gi
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- PPG, Flō-Optics Announce Supplier Agreement for Digitally Applied Optical Coatingshttps://modernod.com/news/ppg-flo-optics-announce-supplier-agreement-for-digitally-applied-optical-coatings/2481849/PPG announced an exclusive supplier agreement with Flō-Optics, a developer of digital manufacturing technology for the ophthalmic industry, for the application of PPG HI-GARD scratch-resistant coatings using Flō’s proprietary digital printing technology. Financial terms of th
- Ocugen Announces Positive Update from the Phase 1/2 Trial of OCU400, a Gene Therapy Candidate for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-update-from-the-phase-12-trial-of-ocu400-a-gene-therapy-candidate-for-the-treatment-of-rp-and-lca/2481836/Ocugen announced a clinical study update for retinitis pigmentosa (RP) participants treated in the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations, and Leber congenital amaurosis (LCA) with mutation(s) in the CE
- Altris Receives FDA Clearance of Altris IMS Platform for OCT Scan Analysishttps://modernod.com/news/altris-receives-fda-clearance-of-altris-ims-platform-for-oct-scan-analysis/2481833/Altris received FDA 510(k) clearance for the Altris IMS, the company’s image, and data management platform. The Altris platform is designed to store, organize, and support in-depth analysis of Optical Coherence Tomography (OCT) scans. The platform provides secu
- NovaBay Pharmaceuticals’ Avenova Allograft is Launched in the United Stateshttps://modernod.com/news/novabay-pharmaceuticals-avenova-allograft-is-launched-in-the-united-states/2481830/NovaBay Pharmaceuticals announced the launch of the Avenova Allograft in the United States through its physician-dispensed channel. The company’s prescription optic allograft, which is intended for use as a protective covering during the repair of ocular surfaces, is manufactured using BioS
- Eye Care Charity Orbis Announces New Partnership with Heidelberg Engineeringhttps://modernod.com/news/eye-care-charity-orbis-announces-new-partnership-with-heidelberg-engineering/2481817/Orbis announced a new partnership with Heidelberg Engineering in which Heidelburg will fund crucial teaching opportunities and research—focusing on training eye care professionals around the world via Cybersight (Orbis’s telemedicine and e-learning p
- SightGlass Vision Reports 4-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenseshttps://modernod.com/news/sightglass-vision-reports-4-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/2481810/SightGlass Vision reported positive 4-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering el
- Atsena Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-announces-first-patient-dosed-in-phase-12-clinical-trial-of-atsn-201-for-the-treatment-of-x-linked-retinoschisis/2481796/Atsena Therapeutics announced the first patient has been dosed in the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 uses AAV.SPR, the company’s novel spreading c